With an assumption of the possible benefit of GM-CSF in COVID-19, a trial is underway with sargramostim, a recombinant humanized GM-CSF, in COVID-19 patients with acute hypoxic respiratory failure (ClinicalTrials.gov Identifier: NCT04326920). Here, CSF2 is linked to COVID-19.